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Human chorionic gonadotropin (hCG) is a heterodimeric mol-
ecule consisting of an a -chain common to all members of the
glycoprotein hormone family (luteinizing hormone (LH), follicle-
stimulating hormone (FSH) and thyroid-stimulating hormone
(TSH)) non-covalently associated with a b -chain unique to each
hormone. However, there is extensive sequence homology be-
tween the different b -chains, with LH exhibiting 85%, TSH 46%,
and FSH 36% homology with the first 114 of the 145 amino acid
residues of hCG. Both the a - and the b -chains are composed of
three loops held in place by a cystine knot of three disulfide
bonds (Lapthorn et al., 1994; Wu et al., 1994), a structural motif
also found in transforming growth factor b (TGF-b ), neuronal
growth factor (NGF), platelet-derived growth factor b (PDGF-b )
and various other growth hormones. One end of both of the sub-
units comprises loops 1 and 3, which in the b -subunit are stabil-
ized by a fourth disulfide bond, while loop 2 forms the other
end of each of the subunits. The a - and b -subunits are oriented
opposite to each other in such a way that the paired loops 1 and
3 form each end of a cigar-like molecule (Fig. 1) with the a -sub-
unit held in place by an additional loop structure in the b -sub-
unit containing two disulfide bonds and referred to as the ‘seat
belt’ (b 91–110). The seat belt is also important in the receptor
binding. The unique C-terminal peptide (CTP, b 113–145) of the
hCGb -subunit protrudes from the compact molecule without
any obviously constrained structure. The hormone is extensively
glycosylated, having two N-linked oligosaccharides on each
chain and, in addition, four O-linked oligosaccharides located
on the serine rich CTP of the b -chain. Although receptor bind-
ing requires intact holo-hormone, hCG can be extracted from
urine and serum in several different molecular species, reflect-
ing different glycoforms, proteolytic fragments and sometimes
the presence of free b -chain. 
After fertilization, hCG is produced from the eight-cell blasto-
cyst stage onwards, and is initially detectable at days 7–12 after
fertilization. Production of hCG is continued by trophoblast cells
and promotes the secretion of progesterone from the corpus
luteum. After 7 weeks, the synthesis of hCG is switched to the
placenta, where the production remains constant until 14–15
weeks, after which time secretion begins to decline. The function
of the placenta-derived hCG is not known. While expression 
of dimeric hCG is associated with trophoblastic neoplasia, 
non-trophoblastic tumours can express hCG ectopically but, in
these tumours, only the b -chain is produced. Therefore, in-
creased serum concentrations of the hormone are used both as
an aid to diagnosis and as a marker of established disease.
Generation of immune responses
A prerequisite for the induction of an immune response against
a protein antigen is that the antigen is taken up by specialized
antigen-presenting cells (APC), such as dendritic cells. After
proteolytic degradation, selected peptide fragments (T cell epi-
topes) are expressed on the cell surface of the APC in associ-
ation with major histocompatibility complex (MHC)-encoded
molecules. When the MHC–peptide complexes are recognized
by antigen-specific T cell receptors on CD4+ helper T cells, the
cells become activated and begin synthesis and secretion of
cytokines that help to stimulate B cells to secrete antigen-
specific antibodies. Small molecules containing no suitable 
T cell epitopes can be made immunogenic by covalently at-
taching larger carrier proteins, such as tetanus toxoid (TT) or
diphtheria toxoid (DT).
T cell epitopes on hCG
Purified hCG in the absence of a carrier protein can elicit an
antibody response in mice and rabbits, implying that one or
both subunits contain appropriate helper T cell epitopes for
these species. After immunization of BALB/c mice, Rouas et al.
(1993) were able to identify two overlapping T cell epitopes on
the a -subunit (residues a 50–70 and a 60–80, respectively) and
two distinct epitopes on the b -subunit which included the
residues b 1–13 and b 11–22. As a part of preliminary studies
aimed at developing an anti-tumour vaccine, Triozzi et al.
(1997) immunized non-HLA-matched human subjects with 
the 37 amino acid CTP covalently linked to DT. Subsequently,
T cell proliferative responses could be obtained after stimu-
lation in vitro with hCG holo-hormone, but not with the CTP in
the absence of a carrier, suggesting that either or both of the 
a - and the b -subunits possess T cell epitopes able to bind to
various HLA class II molecules.
After immunization of BALB/c mice with an expression
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The heterodimeric glycoprotein hormone, human chorionic gonadotropin, has been extensively
characterized in terms of its recognition by mouse monoclonal antibodies. A number of different
approaches have led to the definition of several epitope clusters on the surface of the molecule.
These include epitopes located solely on the a - or b -chain, some of which are masked when the
two chains associate to form the holo-hormone. Additional epitopes comprise amino acids con-
tributed by both the chains. In contrast to the extensive knowledge regarding B cell epitopes,
the characterization of T cell epitopes on hCG has only recently begun to be explored.
plasmid containing the hCGb gene, Geissler et al. (1997) demon-
strated that the b -subunit can induce a cytotoxic T lymphocyte
(CTL) response, suggesting that the hormone also contains se-
quences that can bind to MHC class I molecules. Furthermore,
they found that the induced CTL response could prevent the
growth of a myeloma cell line transfected to express hCGb .
While hCGb CTL epitopes in humans have yet to be defined,
their characterization would clearly facilitate the development
of an hCGb -specific anti-tumour vaccine.
B cell epitopes on hCG
Unlike T cell epitopes, which are short linear peptides derived
from processed antigen, antibodies recognize structures on the
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Fig. 1. Computer-generated space-filling model of hCG highlighting differences between surface-exposed amino acid residues on hCG and
LH. The a -subunit is in red; the residues shared between hCGb and LHb are in green; the hCGb specific residues are in blue and the N-
terminus of the hCGb chain is highlighted in white. The projection of the crystal structure is visualized in four different orientations.
surface of the native antigen. Several groups have isolated and
characterized panels of monoclonal antibodies (mAbs) raised 
in mice against purified or recombinant hCG, hCG fragments,
isolated subunits or specific peptides (Kofler et al., 1981; Kofler
et al., 1982; Bidart et al., 1985; Hojo and Ryan, 1985; Norman et al.,
1985; Berger et al., 1988; Krichevsky et al., 1988; Bottger et al.,
1993; Furui et al., 1994). Since antibodies to globular proteins
most commonly interact with 14–21 amino acids on the surface
of the protein, most of the epitopes on hCG are, by necessity,
discontinuous, made up of amino acids that juxtapose in the
native conformation. This has been confirmed by the loss, or
considerable decrease, of antibody binding after reduction and
alkylation of the free subunits. While some of the mAbs can
bind to short linear peptides, they usually do so with consider-
ably reduced affinity compared with their binding to the native
hormone. The epitope specificities of the antibodies have been
determined using a variety of methods (Table 1). Distinct epi-
tope clusters have been identified that consist of several over-
lapping epitopes with subtle differences recognized by
individual mAbs.
Epitopes on hCGa
Characterization of antibodies derived from immunization
with hCG, FSH, TSH and LH identified three distinct dominant
epitope clusters on the a -subunit, two of which are accessible
on the holo-hormone and a third that is only accessible on the
free a -subunit (Norman et al., 1985; Krichevsky et al., 1988;
Berger et al., 1990; Dirnhofer et al., 1994a). Peptide scanning for
antibody binding sites maps one of these clusters to loop 1 of
the a -chain and includes sequences within a 13–22. This cluster,
AI, reacts with several different mAbs that recognize over-
lapping amino acid residues. The second, spatially distinct epi-
tope cluster on the intact hormone, AII, is conformation-
sensitive, with no linear peptide stretch contributing signifi-
cantly to the antibody recognition. It is also iodination-sensitive
and is located on the third loop involving residues a 65–80.
Immunization with the a -subunit has identified another epi-
tope cluster, AIII, which is masked by the b -subunit in the
native hormone. Since a linear stretch of amino acids con-
tributes to the AIII epitope, it has been mapped to include the
region a 32–41. 
Epitopes on hCGb
There is extensive sequence homology between hCGb
and LHb (Fig. 1). Therefore, it is not surprising that many
hCGb -reactive mAbs also bind to LH, although a number of
mAbs specific for either hCGb or LHb have been produced
(Norman et al., 1985; Berger et al., 1990; Moyle et al., 1990; Bottger
et al., 1993; Dirnhofer et al., 1993, 1994b). We have used site-
specific mutagenesis to characterize the immunogenicity of
hCGb and have found that a single amino acid substitution
b R68E completely eliminates binding of all the hCG/LH cross-
reactive mAbs in the panel of hCG mAbs used (Jackson et al.,
1996). Since each crossreactive mAb has unique but overlapping
contact residues (Fig. 2) located on either loop 1 (residues b 24
and b 25) or loop 3 (residues b 68, b 74, b 75 and b 79), the whole
of the tip of hCGb (and of LHb ; Fig. 1) formed by loops 1 and 3
probably constitutes a single large epitope cluster, BI. This is
perhaps not so surprising when the degree to which this region
protrudes from the rest of the molecule is considered. 
Several distinct hCGb -specific conformation-dependent epi-
tope regions have been characterized. Two of them are exposed
only on the free hCGb subunit and include amino acids
b 20–22/ b 75 (BV) and b 89 (BVI) among their contact residues.
Three distinct hCGb -specific epitope regions (BII–BIV) are
accessible on the native hormone. One of these, BII, maps close
to the cysteine knot and includes residue b 10. BIII includes
amino acids in loop 2 of hCGb (b 38–56) and may have a linear
stretch of amino acids as part of the conformational epitope.
The last epitope cluster, BIV, has been mapped to the seat belt
(b 100–109). Finally, four independent linear epitopes have been
characterized on the CTP. However, because of the high en-
tropy resulting from the flexible conformation of the CTP, these
epitopes may be relatively weakly immunogenic when intact
hCGb is encountered by the immune system.
Epitopes present only on the holo-hormone
A number of mAbs have been described that recognize
native hCG but do not react with either of the free subunits.
Antibody competition with subunit-specific mAbs has defined
a single epitope cluster in the junction between the cysteine
knot, loop 2 of the b -subunit and loop 1 of the a -subunit
(Norman et al., 1985; Schwartz et al., 1986; Krichevsky et al.,
1988; Bottger et al., 1993). This epitope cluster, CI, includes the
recognition sequences for several different mAbs, which bind
to distinct but overlapping epitopes. 
Topographic relationship of the epitopes
We have devised a method to relate the spatial location of
different epitope clusters to each other using a synergistic bind-
ing assay where two or three mAbs are cross-linked by im-
mobilization on the same surface (Klonisch et al., 1996a,b).
Simultaneous binding of radiolabelled hCG to the cross-linked
mAbs results in binding constants greater than the sum of the
binding constants for the individual mAbs. This synergistic
binding occurs when the epitopes on the surface of the hor-
mone are spatially distinct and orientated in the same plane so
as to cause minimal torsion in antibody–antigen interaction. For
example, a 50-fold increase in the binding constant was observed
for a BI (mAb 3E2)–AI (mAb INN-hFSH-123) combination,
suggesting that the Fab arms of the antibodies could interact
with their epitopes with maximal loss of free energy. Some, but
not all, members of the BI cluster could synergize with certain
mAbs binding to the AI epitope cluster, to the CI cluster and to
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Table 1. Methods used for epitope mapping of hCG
Chemical modification of the hormone
Enzymatic fragmentation
Peptide scanning with overlapping peptides
Binding to hormones from different species
Binding to related hormones (FSH, LH, TSH)
Binding to LH/CG chimeric polypeptide chains
Site-specific mutagenesis
Competition binding with two or more mAbs
Synergistic binding with two or more mAbs
Interference with hormone–receptor interaction
the BII cluster. The BII cluster allowed synergistic binding to
mAbs from the AI cluster. This suggests that the AI, and part of
the BI, BII and CI clusters are orientated in the same topographic
plane. mAbs recognizing epitopes in the AI and AII clusters
could also bind synergistically. One of the mAbs recognizing a
linear (although not fully characterized) epitope on the CTP
(mAb 3G12) and which has very little innate binding affinity
towards the intact hormone was able to bind synergistically
with mAbs from many epitope clusters on both the a - and b -
subunits and on the holo-hormone by substantially lowering
the dissociation constant for the antigen–antibody interaction. 
The hCG/LH receptor interacts with sequences on both sub-
units of hCG, and a model has been proposed in which the re-
ceptor may bind the hormone like a horseshoe (Jiang et al.,
1995). Receptor binding involves residues that contribute to the
formation of epitope clusters CI, BII, AI and part of BIII on loop
2 and to residues b 93–100 on the seat belt, which may con-
tribute to the cluster BIV. In addition, part of the sequences on
the hCG-unique CTP can interact with the receptor and are
needed for transmission of the hCG-specific signal. Therefore,
the receptor interaction will block the binding of a number of
the hCG mAbs, but some epitopes still remain accessible
(Schwarz et al., 1991; Cosowsky et al., 1995). Binding of mAbs
directed to most of the BI cluster is unaffected by ligation of 
the hormone to its receptor, implying that hCG binds in an
orientation that results in the b -loops 1 and 3 projecting from
the cell surface. Consistent with our observation that the AI
and AII clusters allow synergistic binding is the fact that mAbs
to the AII cluster, but not to the AI cluster, bind to the hor-
mone–receptor complex. Evidence has been presented that an
antibody that recognizes amino acids within the AI cluster
(mAb HT13) can bind to hCG complexed with a soluble form of
the receptor but that the epitope recognized is not accessible
when the hormone is bound to the full length receptor, suggest-
ing that the epitope recognized by this particular antibody may
be in close contact with the transmembrane region of the recep-
tor (Pantel et al., 1993).
Epitopes on hCG recognized by the human immune
response
The glycoprotein hormones are ‘self’ antigens. Although nor-
mally expressed only during pregnancy, it appears that hCG is
very effective at establishing immunological tolerance. There
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INN-hCG-2	 CG	 BII
INN-hCG-32	 CG	 BII
INN-hCG-22	 CG/LH	 BI
INN-bLH-1	 CG/LH	 BI
INN-hCG-111	 CG/LH	 BI
INN-hCG-24	 CG/LH	 BI
INN-hCG-58	 CG/LH	 BI
INN-hCG-51	 CG/LH	 BI
INN-hCG-20	 CG/LH	 BI
3E2	 CG/LH	 BI
INN-hCG-64	 CG β	 BV
INN-hCG-22	 CG β	 BVI
OT3A	 CTP	 BVII
mAb Specificity WT K20N
E21R
G22E
P24H
V25Y
R68E
R74S
G75H
V79H
K20N
E21R
G22E
P24H
V25Y
P24H V25Y R68E R74S
G71R
G75H V79H R74S
Fig. 2. Binding of a panel of mAbs (Schwartz et al., 1986; Berger et al., 1990; Dirnhofer et al., 1994a,b) to wild type (WT) and mutant hCGb
chain (Jackson et al., 1997) expressed on the surface of COS cells. Amino acid substitutions in the mutants are indicated using the single
amino acid code to indicate the wild type amino acid, the position in the hCGb sequence, and the amino acid in the mutant. The binding of
the mAbs is expressed relative to the binding of mAb OT3A, which recognizes a linear epitope (b 133–39) on the C-terminus. Green >70%
binding; orange, 50–70% binding; yellow, 20–30% binding; red <10% binding.
are hardly any reports of circulating autoantibodies to the
hormone being detected in humans, even in patients with a
history of recurrent spontaneous abortion (Tulppala et al., 1992).
However, it is also clear that this tolerance is not absolute,
because when it is administered coupled to a potent carrier and
in the presence of adjuvant, hCG can break tolerance and elicit
an immune response.
The important function of the hormone as an inducer of pro-
gesterone in the corpus luteum has prompted a number of lab-
oratories to develop potential antifertility vaccines based on
hCGb . In addition, the ectopic expression of hCGb in certain
tumours makes the hormone a suitable candidate for a cancer
vaccine (Acevedo et al., 1995; Geissler et al., 1997). Two separate
strategies have been pursued in which the antifertility vaccine
candidates have undergone phase I and II trials. The World
Health Organisation (WHO) has for many years supported a
vaccine development programme based upon the unique hCG
CTP (Jones et al., 1988). The antibodies elicited do not appear to
block hormone–receptor interaction, suggesting that the anti-
fertility effect relies essentially on Fc receptor-mediated clear-
ance of the antibody–hCG complexes. The Indian Government
has promoted a vaccine programme based upon a hetero-
species dimer (HSD) composed of an ovine a -chain associated
with the hCGb -subunit (Talwar et al., 1994). Eighty-five per
cent of women immunized with this vaccine were transiently
protected against pregnancy. Immunization with the HSD
induces an LH crossreactive antibody response. Although no
adverse biological side effects have so far been observed in the
vaccinees, it is not known if long-term exposure to the HSD
will induce undesired autoimmune responses to LH in im-
munized women. Therefore, we have embarked upon a pro-
gramme aimed at selectively deleting the crossreactive epitopes
so that the antifertility or antitumour vaccine contains only 
the relevant hCGb specific epitopes (Jackson et al., 1996; Delves
et al., 1997). 
Although the epitopes recognized by a very large number of
mouse mAbs have been characterized, less is known regarding
which hCG epitopes dominate the human polyclonal antibody
response in vivo. In mice, the epitopes used are determined 
by the antigen receptors on the mouse B cells, which, owing 
to sequence differences, are unlikely to have the same fine
specificity as the antigen receptors in humans. Therefore, the
epitope usage in humans cannot be predicted on the basis of
the epitope characterization using mouse-derived mAbs.
However, an indication of the epitope usage in humans has
been obtained using sera from the vaccinees in the Indian
phase I and II trials. In competition ELISAs using four mouse
mAbs (B206, a LH-crossreactive mAb binding to BI; 357-2,
which binds to the BIII cluster on hCGb ; 218, binding to CI; 
and P233 specific for A1), only B206 was able to significantly
(40–90%) inhibit the binding of the human antisera to hCG
(Deshmukh et al., 1993). This suggests that the crossreactive 
BI epitope cluster is the most dominant in humans in vivo,
although additional epitope clusters may also be used. 
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